CJC-1295 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-04. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
Chemical ligation is the chemoselective condensation of unprotected peptide segments enabled by the formation of a non-native bond at the ligation site. Chemical ligation is usually carried out in aqueous solution. Multiple consecutive chemical ligation reactions can be used to make proteins of the typical size found in nature, i.e. with polypeptide chains containing 200–300 amino acids, produced by total synthesis.
In September 2019, Collins released her debut perfume, Diva Pink. The unisex fragrance has a guaiac wood, saffron, rose and sandalwood scent, and is described as a "sensual fragrance with luxury oud and diva day undertones". Collins has also launched two lipsticks, "Candy" and "Diva" as well as her own range of false eyelashes. In March 2020, Collins announced her collaboration with fashion company InTheStyle, to release a collection of T-shirts, sweaters, hoodies and pyjamas featuring her viral quotes and memes. Following the success of the range, Collins collaborated with the company again in September, debuting her first plus-size collection with the brand which featured dresses, blouses and a selection of loungewear. During the COVID-19 pandemic, Collins released her own range of hand sanitizers and face masks. Following her weight loss, Collins began selling her old clothes on the online marketplace apps Depop and Vinted. In March 2021, Collins teamed up with The London Aesthetics Company to release GemmaCollagen, her own anti-ageing collagen supplement and skincare regime. Collins, who is regularly complimented on her skin, worked alongside the company's director Amrit Bhandal to create an ultimate skincare collection which included a cleanser, a toner, a day cream and a facial mask, as well as an eye serum and an amino acid night repair serum. The company also created a marine collagen supplement that included 90 capsules and was said to positively benefit the skin, hair, joints and muscles.
== Materials and techniques == In the late 1990s, with the huge popularity of surgical rejuvenation and the concomitant increase of cosmetic surgery procedures worldwide, more substances, along with biocompatible materials commonly used in other medical applications for years, became available to surgeons for use in augmenting thinning or misshapen lips into more plump and attractive features. Some of the first widely used lip augmentation substances were:
Robert Culp at IMDb Robert Culp at the TCM Movie Database Robert Culp at the Internet Broadway Database Robert Culp at the Internet Off-Broadway Database (archived) Robert Culp at The Interviews: An Oral History of Television
It is descriptive rather than prescriptive. Bias and unfairness may go undetected because the developers are overwhelmingly white and male: among AI engineers, about 4% are black and 20% are women. There are various conflicting definitions and mathematical models of fairness. These notions depend on ethical assumptions, and are influenced by beliefs about society. One broad category is distributive fairness, which focuses on the outcomes, often identifying groups and seeking to compensate for statistical disparities. Representational fairness tries to ensure that AI systems do not reinforce negative stereotypes or render certain groups invisible. Procedural fairness focuses on the decision process rather than the outcome. The most relevant notions of fairness may depend on the context, notably the type of AI application and the stakeholders. The subjectivity in the notions of bias and fairness makes it difficult for companies to operationalise them. Having access to sensitive attributes such as race or gender is also considered by many AI ethicists to be necessary in order to compensate for biases, but it may conflict with anti-discrimination laws. At the 2022 ACM Conference on Fairness, Accountability, and Transparency a paper reported that a CLIP‑based (Contrastive Language-Image Pre-training) robotic system reproduced harmful gender‑ and race‑linked stereotypes in a simulated manipulation task.
Sources: en.wikipedia.org
Evidence of intentional pyre cremation at the HOR-1 site (Malawi) approximately 9500 years before present, representing the oldest adult pyre cremation in the world reported to date, is presented by Cerezo-Román et al. (2026). Chritz et al. (2026) reconstruct the subsistence of foragers and herders from eastern Africa living from 9500 to 230 years before present on the basis of isotopic values of their tooth enamel and bone collagen, reporting evidence dietary diversity in fisher-foragers and in earliest pastoralists from the Turkana Basin (Kenya), and evidence that specialized pastoralist diets happened approximately 1000 years after the introduction of domestic livestock. Martin et al. (2026) reconstruct the human population history in northeastern Africa on the basis of the study of the morphology of bony labyrinths of Late Pleistocene and Holocene individuals, reporting evidence of overall biological discontinuity between foragers and Neolithic food producers in the Middle Nile Valley, but also evidence of limited, localized instances of admixture or continuity between the two groups. Surovell et al. (2026) provide new information on the age of the purported pre-Clovis site Monte Verde II (Chile), and argue that the site cannot be older than the middle Holocene. The first molecular evidence of HPV16 in ancient anatomically modern humans is reported from the study of ancient DNA of the Ust'-Ishim man and Ötzi by Yazigi et al. (2026). Balzeau et al.
== External links == Histology image: 77_04 at the University of Oklahoma Health Sciences Center – "Slide 77 skeletal muscle" Anatomy Atlases – Microscopic Anatomy, plate 05.83 – "Smooth Muscle" Diagram at kctcs.edu
== Principles and history == Water was the original coolant for internal combustion engines. It is cheap, nontoxic, and has a high heat capacity. It however has only a 100 Kelvin liquid range, and it expands upon freezing. To address these problems, alternative coolants with improved properties were developed. Freezing and boiling points are colligative properties of a solution, which depend on the concentration of dissolved substances. Salts, for example, lower the melting points of aqueous solutions and as such are commonly used for de-icing due to their low cost. However, salt solutions typically cannot be used in cooling systems because they induce corrosion of metals. Solutions of organic compounds, especially alcohols, in water are effective. Alcohols such as methanol, ethanol, ethylene glycol, etc. have been the basis of all antifreezes since they were commercialized in the 1920s.
Clayton (1956), fiction writer, novelist Robert Silverberg (1956), science fiction writer, recipient of the Damon Knight Memorial Grand Master Award in 2004 Paul Zweig (1956), poet, memoirist, 1976 Guggenheim Fellow George Bellak (1957), television writer Richard P. Brickner (1957), writer, 1983 Guggenheim Fellow Raymond Federman (1957), French–American novelist and academic; author, Double or Northing Lawrence Shainberg (1958), writer of Zen Buddhism Jerome Charyn (1959), novelist Jay Neugeboren (1959), novelist, essayist, short story writer Robert T.
Sources: en.wikipedia.org
== History == Acetalated dextran was first reported in 2008 out of the lab of Jean Fréchet at the University of California, Berkeley in the College of Chemistry by inventors Eric Bachelder, Tristan Beaudette and Kyle Broaders. This version of acetalated dextran, often abbreviated Ac-DEX, has dextran and exceedingly low levels of acetone and methanol as degradation products. In 2012, in the laboratory of Kristy Ainslie, at Ohio State University in the College of Pharmacy, polymer synthesis was modified to release ethanol in place of methanol upon degradation. The ethanol producing version of acetalated dextran is often abbreviated Ace-DEX.
==== I. Lipophilic Drugs ==== Microbubbles can facilitate the local targeting of hydrophobic drugs through the incorporation of these agents into the microbubble lipid shell. This encapsulation technique reduces systemic toxicity, increases drug localization, and improves the solubility of hydrophobic drugs. For increased localization, a targeting ligand can be appended to the exterior of the microbubble. This improves treatment efficacy. One drawback of the lipid-encapsulated microbubble as a drug delivery vehicle is its low payload efficacy. To combat this, an oil shell can be incorporated to the interior of the lipid monolayer to enhance payload efficacy.
=== Nonspecific === In as many as 90 percent of cases, no physiological causes or abnormalities on diagnostic tests can be found. Nonspecific back pain can result from back strain or sprains, which can cause peripheral injury to muscle or ligaments. Many patients cannot identify the events or activities that may have caused the strain. The pain can present acutely but in some cases can persist, leading to chronic pain. Chronic back pain in people with otherwise normal scans can result from central sensitization, in which an initial injury causes a longer-lasting state of heightened sensitivity to pain. This persistent state maintains pain even after the initial injury has healed. Treatment of sensitization may involve low doses of antidepressants and directed rehabilitation such as physical therapy.
=== Synthesis === The synthesis of tirzepatide was first disclosed in patents filed by Eli Lilly and Company in 2016. This uses standard solid phase peptide synthesis, with an allyloxycarbonyl protecting group on the lysine at position 20 of the linear chain of amino acids, allowing a final set of chemical transformations in which the sidechain amine of that lysine is derivatized with the lipid-containing fragment. Large-scale manufacturing processes have been reported for this compound.
From the mid-1960s onward, Ramachandran continued studying crystallography, including the conformation of peptides including types of β-turns, conformation of prolyl residues, cis-peptide units, occurrence and need for non-planarity of the peptides, NMR coupling constants and peptides containing L and D residues, among other tops. He was awarded the prestigious Jawarharlal Nehru Fellowship in 1968 for research on Protein and Polypeptide Conformation; he was one of its first recipients. Ramachandran can be credited for bringing together into the one field of molecular biophysics the then disparate fields of X-ray crystallography, peptide synthesis, NMR and other optical studies, and physico-chemical experimentation. In 1970, he founded the Molecular Biophysics Unit at the Indian Institute of Science which was later known as the Centre of Advanced Study in Biophysics. Ramachandran and A.V. Lakshminarayanan developed convolution-backprojection algorithms which greatly improved the quality and practicality of results obtainable by x-ray tomography. Compared to previously used methods, their algorithms considerably reduced computer processing time for image reconstruction, as well as providing more numerically accurate images. As a result, commercial manufacturers of x-ray tomographic scanners started building systems capable of reconstructing high resolution images that were almost photographically perfect. In 1971, they published their research in PNAS. In 1981, Ramachandran became a founding member of the World Cultural Council.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.